Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose rhIL-2 in Recently Diagnosed Type 1 Diabetes
NCT02411253Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2015
- Primary completion
- Nov 2020
- Modality
- Cytokines & Interferons
- Countries
- 6
01
Overview
A Phase 2 trial of aldesleukin in type 1 diabetes mellitus (T1D), sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2015; status: completed.
02
Drugs
aldesleukin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02411253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411253.